JPMorgan Chase & Co. Boosts Bruker (NASDAQ:BRKR) Price Target to $55.00

Bruker (NASDAQ:BRKR) had its target price hoisted by investment analysts at JPMorgan Chase & Co. from $50.00 to $55.00 in a report released on Monday,Benzinga reports. The firm presently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 20.52% from the company’s previous close.

A number of other research firms have also recently commented on BRKR. Rothschild Redb raised shares of Bruker to a “strong-buy” rating in a report on Thursday, November 20th. UBS Group upped their price target on shares of Bruker from $40.00 to $43.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. Weiss Ratings restated a “sell (d)” rating on shares of Bruker in a research report on Monday, December 1st. The Goldman Sachs Group initiated coverage on Bruker in a research report on Tuesday, December 9th. They issued a “sell” rating and a $40.00 target price for the company. Finally, Wells Fargo & Company upped their price objective on Bruker from $48.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $52.86.

Bruker Price Performance

BRKR stock traded up $0.51 during mid-day trading on Monday, hitting $45.64. The stock had a trading volume of 643,271 shares, compared to its average volume of 2,784,217. The firm has a fifty day simple moving average of $41.68 and a 200 day simple moving average of $38.33. The firm has a market capitalization of $6.93 billion, a P/E ratio of -285.53, a P/E/G ratio of 6.64 and a beta of 1.17. The company has a current ratio of 1.85, a quick ratio of 0.91 and a debt-to-equity ratio of 0.81. Bruker has a 52 week low of $28.53 and a 52 week high of $64.64.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The business had revenue of $860.50 million for the quarter, compared to analysts’ expectations of $847.40 million. During the same period last year, the firm posted $0.60 earnings per share. The firm’s quarterly revenue was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, research analysts forecast that Bruker will post 2.69 EPS for the current year.

Insider Activity at Bruker

In related news, Director John A. Ornell sold 6,233 shares of the firm’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $39.00, for a total transaction of $243,087.00. Following the transaction, the director directly owned 35,212 shares of the company’s stock, valued at $1,373,268. This trade represents a 15.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 27.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Bruker

A number of large investors have recently made changes to their positions in the stock. Allworth Financial LP grew its holdings in Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after buying an additional 257 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in Bruker by 9,800.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 4,851 shares of the medical research company’s stock valued at $158,000 after purchasing an additional 4,802 shares during the period. Armistice Capital LLC purchased a new position in shares of Bruker during the 3rd quarter valued at $321,000. Dark Forest Capital Management LP boosted its stake in Bruker by 256.0% during the third quarter. Dark Forest Capital Management LP now owns 71,779 shares of the medical research company’s stock valued at $2,332,000 after buying an additional 51,614 shares during the period. Finally, XTX Topco Ltd bought a new position in shares of Bruker during the third quarter valued at about $589,000. 79.52% of the stock is owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.